Vai al contenuto principale
Coronavirus: aggiornamenti per la comunità universitaria / Coronavirus: updates for UniTo Community
Foto gruppo

di Neuro-Oncologia di rilevanza nazionale

Componenti

Fotografia

Attività

Il Gruppo di Ricerca si occupa di tumori primitivi e secondari del sistema nervoso e di complicanze neurologiche dei tumori extranervosi e delle relative terapie. Sono attivi diversi filoni di ricerca. Il principale filone annovera studi clinico-traslazionali, istituzionali o multi-istituzionali, italiani o internazionali, di fase II e III relativi a : nuovi farmaci molecolari nel glioblastoma (vaccinazione anti-vIII EGFR, neratinib, buparlisib, ipilimumab, nivolumab); nuovi farmaci antiangiogenetici nel glioblastoma, nel glioma di grado II e II (bevacizumab); nuovi farmaci molecolari nel medulloblastoma (vismodegib); nuovi farmaci antiangiogenetici nell’ependimoma (bevacizumab); nuovi agenti molecolari nei linfomi cerebrali primitivi (rituximab); nuovi farmaci antiepilettici (lacosamide); studio EORTC 26053 su chemioterapia concomitante e adiuvante con temozolomide nel glioma anaplastico senza delezione di 1p/19q, di cui è Coordinatore Nazionale; studio IELSG nei linfomi cerebrali primitivi di nuova diagnosi; studio prospettico sull’impiego della citarabina liposomiale nelle meningiti neoplastiche da neoplasia cerebrale primitiva in associazione a terapia sistemica. Un secondo filone di ricerca è relativo al monitoraggio delle terapie con tecniche di neuroimmagine avanzata, quali MR spettroscopica/ perfusionale, DTI, PET con FDG e Metionina (in collaborazione con la Neuroradiologia dell’Università Vita-Salute, Ospedale San Raffaele, Milano e la Neurology/ Nuclear Medicine dell’Ospedale Universitario di Aarau, Svizzera). Un terzo filone di ricerca riguarda la chemioterapia preoperatoria dei gliomi di grado II (in collaborazione con le Neurochirurgia dell’Università Statale di Milano, Ospedale Istituto Clinico Humanitas). Un quarto filone di ricerca è il monitoraggio cognitivo e di qualità della vita di pazienti con gliomi trattati con farmaci antiangiogenetici. Un quinto filone di ricerca consiste nella ricerca/validazione di biomarkers molecolari a scopo prognostico/predittivo nei gliomi. Infine il gruppo di ricerca partecipa al CERN (Collaborative Ependymoma Research Network, US) che ha l’obiettivo di identificare profili molecolari di significato prognostico negli ependimomi.

Settore ERC del gruppo:
LS4_6 - Cancer and its biological basis
LS5_10 - Neuroimaging and computational neuroscience
LS5_3 - Neurochemistry and neuropharmacology
LS5_7 - Cognition (e.g. learning, memory, emotions, speech)
LS7_2 - Diagnostic tools (e.g. genetic, imaging)
LS7_3 - Pharmacology, pharmacogenomics, drug discovery and design, drug therapy
LS7_8 - Health services, health care research

Prodotti della ricerca

Trevisan E, Bertero L, Magistrello M, Ruda R, Soffietti R. (2015) Is there a Role for Bevacizumab in Non-Glial Tumors? Current drug targets [PMID]

Vidone M, Clima R, Santorsola M, Calabrese C, Girolimetti G, Kurelac I, Amato LB, Iommarini L, Trevisan E, Leone M, Soffietti R, Morra I, Faccani G, Attimonelli M, Porcelli AM, Gasparre G. (2015) A comprehensive characterization of mitochondrial DNA mutations in glioblastoma multiforme. The international journal of biochemistry & cell biology [DOI  PMID]

Soffietti R, Bertero L, Pinessi L, Ruda R. (2014) Pharmacologic therapies for malignant glioma: a guide for clinicians. CNS drugs 28(12) 1127-37 [DOI  PMID]

Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS. (2014) Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-oncology [DOI  PMID]

Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W. (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. The Lancet. Oncology 15(9) e395-403 [DOI  PMID]

Valentini V, Abrahamsson PA, Aranda SK, Astier A, Audisio RA, Boniol M, Bonomo L, Brunelli A, Bultz B, Chiti A, De Lorenzo F, Eriksen JG, Goh V, Gospodarowicz MK, Grassi L, Kelly J, Kortmann RD, Kutluk T, Plate A, Poston G, Saarto T, Soffietti R, Torresin A, van Harten WH, Verzijlbergen JF, von Kalle C, Poortmans P. (2014) Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals of Oncology 25(1): 9-15, 2014). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 25(9) 1863-5 [DOI  PMID]

Chamberlain M, Soffietti R, Raizer J, Ruda R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L, van den Bent M, Wen PY, Jaeckle KA. (2014) Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro-oncology 16(9) 1176-85 [DOI  PMID]

Fiano V, Trevisan M, Trevisan E, Senetta R, Castiglione A, Sacerdote C, Gillio-Tos A, De Marco L, Grasso C, Magistrello M, Tondat F, Ruda R, Cassoni P, Soffietti R, Merletti F. (2014) MGMT promoter methylation in plasma of glioma patients receiving temozolomide. Journal of neuro-oncology 117(2) 347-57 [DOI  PMID]

Trevisan E, Bertero L, Bosa C, Magistrello M, Pellerino A, Ruda R, Soffietti R. (2014) Antiangiogenic therapy of brain tumors: the role of bevacizumab. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 35(4) 507-14 [DOI  PMID]

Soffietti R, Trevisan E, Ruda R. (2014) What have we learned from trials on antiangiogenic agents in glioblastoma? Expert review of neurotherapeutics 14(1) 1-3 [DOI  PMID]

Soffietti R, Trevisan E, Ruda R. (2014) Neurologic complications of chemotherapy and other newer and experimental approaches. Handbook of clinical neurology 121 1199-218 [DOI  PMID]

Weller M, Soffietti R, Brada M. (2014) The legend of cytomegalovirus and glioblastoma lives on. Neuro-oncology 16(1) 166 [DOI  PMID]

Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S. (2014) Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro-oncology 16(2) 173-8 [DOI  PMID]

Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G, Ruda R. (2014) Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). Journal of neuro-oncology 116(3) 533-41 [DOI  PMID]

Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY. (2013) Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. The Lancet. Oncology 14(10) e407-16 [DOI  PMID]

Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY. (2013) Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. The Lancet. Oncology 14(10) e396-406 [DOI  PMID]

Soffietti R. (2013) Reply to M.C. Chamberlain and C. Gemici. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31(20) 2636-7 [PMID]

Ruda R, Magliola U, Bertero L, Trevisan E, Bosa C, Mantovani C, Ricardi U, Castiglione A, Monagheddu C, Soffietti R. (2013) Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro-oncology 15(12) 1739-49 [DOI  PMID]

Lolli I, Morra I, Cimmino A, Trevisan E, Ruda R, Piombino M, Campanella G, Gillio Tos A, De Marco L, Trevisan M, Fiano V, Soffietti R. (2013) Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31(23) e394-7 [DOI  PMID]

Soffietti R. (2013) Ependymoma: current treatment options and a look to the future. CNS oncology 2(3) 223-5 [DOI  PMID]

Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert MR, Aldape KD. (2013) Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain pathology (Zurich, Switzerland) 23(5) 584-94 [DOI  PMID]

Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Mueller RP, Tridello G, Collette L, Bottomley A. (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31(1) 65-72 [DOI  PMID]

Ruda R, Bello L, Duffau H, Soffietti R. (2012) Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro-oncology 14 Suppl 4 iv55-64 [DOI  PMID]

Preusser M, Winkler F, Collette L, Haller S, Marreaud S, Soffietti R, Klein M, Reijneveld JC, Tonn JC, Baumert BG, Mulvenna P, Schadendorf D, Duchnowska R, Berghoff AS, Lin N, Cameron DA, Belkacemi Y, Jassem J, Weber DC. (2012) Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. European journal of cancer (Oxford, England : 1990) 48(18) 3439-47 [DOI  PMID]

Soffietti R, Trevisan E, Ruda R. (2012) Targeted therapy in brain metastasis. Current opinion in oncology 24(6) 679-86 [DOI  PMID]

Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, Ledoux A, Wilson C, Long L, Gilbert MR, Aldape K. (2012) A prognostic gene expression signature in infratentorial ependymoma. Acta neuropathologica 123(5) 727-38 [DOI  PMID]

Soffietti R, Ducati A, Ruda R. (2012) Brain metastases. Handbook of clinical neurology 105 747-55 [DOI  PMID]

Newton HB, Ruda R, Soffietti R. (2012) Ependymomas, neuronal and mixed neuronal-glial tumors, dysembroblastic neuroepithelial tumors, pleomorphic xanthoastrocytomas, and pilocytic astrocytomas. Handbook of clinical neurology 105 551-67 [DOI  PMID]

Ruda R, Trevisan E, Soffietti R. (2012) Low-grade gliomas. Handbook of clinical neurology 105 437-50 [DOI  PMID]

Soffietti R, Trevisan E, Bertero L, Bosa C, Ruda R. (2012) Anti-angiogenic approaches to malignant gliomas. Current cancer drug targets 12(3) 279-88 [PMID]

Ultimo aggiornamento: 11/06/2015 15:26
Location: https://www.neuroscienze.unito.it/robots.html
Non cliccare qui!